Outlook Therapeutics, Inc. OTLK 深 沪
等待开盘 03-26 09:30:00 美东时间
0.2103
+0.012
+6.16%
华盛通- 最 高0.2222
- 今 开0.20
- 成交量 453.94万股
- 最 低 0.1981
- 昨 收 0.1981
- 总市值 1746.90万
- 52周最高 3.39
- 市盈率 静 --
- 换手率 5.46%
- 52周最低 0.1611
- 委 比 84.62%
- 总股本 8306.72万
- 历史最高 219.20
- 量 比 1.00
- 振 幅 12.17%
- 历史最低 0.1611
- 每 手 1
- 风险率 0.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Outlook Therapeutics stock slides after pricing $5M offering
Outlook Therapeutics (OTLK) shares fell 34% in premarket trading Tuesday after the company priced a public offering. The biopharma firm is selling 20M shares along with warrants to buy up to 20M share...
03-24 19:11
Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global Partners and other stocks moved.
03-24 17:31
Outlook Therapeutics launches public offering; shares down
Outlook Therapeutics (OTLK) has initiated a best-efforts public offering of common stock and accompanying warrants. The offering may include pre-funded warrants in place of common stock. The offering ...
03-24 05:41
Outlook Therapeutics Reveals Proposed Public Offering; No Size Disclosed
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts
03-24 05:35
Outlook Therapeutics Announces Proposed Public Offering
Outlook Therapeutics, Inc. announced the launch of a public offering of its common stock and warrants, with proceeds intended for working capital and general corporate purposes. H.C. Wainwright & Co. serves as the exclusive placement agent. The offering is under a shelf registration statement, and a prospectus supplement will be filed with the SEC. The company, focused on enhancing care for retina diseases, aims to commercialize its ophthalmic be...
03-23 21:30
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
03-11 20:19
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $6
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target from $10 to $6.
03-11 17:52
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor
The latest update is out from Outlook Therapeutics ( ($OTLK) ). At its annual m...
03-11 10:35
Outlook Therapeutics Evaluating Available Regulatory Options To Move Ahead ONS-5010/LYTENAVA Toward Potential U.S. Approval After FDA Meeting
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A
03-06 05:26
